Regeneron Pharmaceuticals (REGN) Set to Announce Quarterly Earnings on Thursday

Regeneron Pharmaceuticals (NASDAQ:REGN) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $8.07 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the previous year, the business posted $10.96 EPS. The business’s quarterly revenue was up .6% on a year-over-year basis. On average, analysts expect Regeneron Pharmaceuticals to post $39 EPS for the current fiscal year and $40 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $890.66 on Wednesday. Regeneron Pharmaceuticals has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a market capitalization of $97.76 billion, a P/E ratio of 25.63, a P/E/G ratio of 2.54 and a beta of 0.11. The company’s fifty day moving average price is $945.77 and its two-hundred day moving average price is $895.19.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. In the last three months, insiders sold 10,195 shares of company stock valued at $9,759,898. Company insiders own 8.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $977.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.